Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma

被引：33

作者：

Valcamonico, Francesca ^{[1
]}

Ferrari, Vittorio ^{[1
]}

Amoroso, Vito ^{[1
]}

Rangoni, Giovanni ^{[1
]}

Simoncini, Edda ^{[1
]}

Marpicati, Patrizia ^{[1
]}

Vassalli, Lucia ^{[1
]}

Grisanti, Salvatore ^{[1
]}

Marini, Giovanni ^{[1
]}

机构：

[1] Spedali Civili Brescia, Dept Med Oncol, Brescia, Italy

来源：

JOURNAL OF NEURO-ONCOLOGY | 2009年 / 91卷 / 01期

关键词：

Advanced renal cell carcinoma; Sorafenib; Brain metastases; ANTITUMOR-ACTIVITY; TRIAL;

D O I：

10.1007/s11060-008-9676-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We report the case of a 75-year old woman who received sorafenib (Nexavar (R), Bayer Pharmaceuticals Corporation, West Haven, CT) for a CNS relapse of clear cell renal cell carcinoma. After four months of sorafenib treatment, a brain magnetic resonance imaging showed 95%-volumetric regression of cerebral metastasis. To the best of our knowledge, this is the first almost complete resolution of brain metastases in renal cell carcinoma treated with sorafenib that has been described.

引用

页码：47 / 50

页数：4

共 50 条

[31] Successful Treatment of Renal Cell Carcinoma With Sorafenib After Effective but Hepatotoxic Sunitinib Exposure [J].

Westgeest, Hans M. ;

van Erp, Nielka P. ;

Honeywell, Richard J. ;

Hoekstra, Ronald ;

Peters, Godefridus J. ;

Verheul, Henk M. W. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06) :E83-E86

[32] Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency [J].

Khan, G. ;

Golshayan, A. ;

Elson, P. ;

Wood, L. ;

Garcia, J. ;

Bukowski, R. ;

Rini, B. .

ANNALS OF ONCOLOGY, 2010, 21 (08) :1618-1622

[33] Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma [J].

Neuhaus, Thomas ;

Luyken, Joachim .

TARGETED ONCOLOGY, 2012, 7 (04) :247-251

[34] Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma [J].

Thomas Neuhaus ;

Joachim Luyken .

Targeted Oncology, 2012, 7 :247-251

[35] Clinical biomarkers of response in advanced renal cell carcinoma [J].

Ravaud, A. ;

Schmidinger, M. .

ANNALS OF ONCOLOGY, 2013, 24 (12) :2935-2942

[36] Oral metronomic cyclophosphamide in advanced ovarian cancer: long-lasting clinical response in an elderly frailty patient [J].

Villa, Michela ;

Attianese, Daniela ;

Petracchini, Massimo ;

Ferrero, Annamaria .

ANTI-CANCER DRUGS, 2019, 30 (09) :964-968

[37] Incidence of brain metastases in renal cell carcinoma treated with sorafenib [J].

Massard, C. ;

Zonierek, J. ;

Gross-Goupil, M. ;

Fizazi, K. ;

Szczylik, C. ;

Escudier, B. .

ANNALS OF ONCOLOGY, 2010, 21 (05) :1027-1031

[38] Erythema Multiforme Induced by Sorafenib for Metastatic Renal Cell Carcinoma [J].

Ikeda, Masaomi ;

Fujita, Tetsuo ;

Mii, Sumiyuki ;

Tanabe, Ken-ichi ;

Tabata, Ken-ichi ;

Matsumoto, Kazumasa ;

Satoh, Takefumi ;

Iwamura, Masatsugu .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (09) :820-824

[39] Sorafenib in der Therapie des fortgeschrittenen NierenzellkarzinomsSorafenib in the treatment of advanced renal cell carcinoma [J].

C. Doehn ;

H.-D. Peters .

Der Onkologe, 2006, 12 (10) :1043-1053

[40] Preoperative induction with sorafenib pathologically downstaged advanced renal cell carcinoma: A case report [J].

Kinoshita, Tatsuya ;

Inoue, Hitoshi ;

Kinouchi, Toshiro ;

Kobayashi, Masao ;

Takada, Tsuyoshi ;

Hara, Tsuneo ;

Hatano, Koji ;

Nonomura, Norio .

INTERNATIONAL JOURNAL OF UROLOGY, 2010, 17 (03) :286-288

← 1 2 3 4 5 →